J. Katsikis et al., The molecular basis for the aberrant production of plasminogen activator inhibitor type 2 in THP-1 monocytes, THROMB HAEM, 84(3), 2000, pp. 468-473
Plasminogen activator inhibitor type 2 (PAI-2) is a urokinase inhibitor tha
t:is expressed primarily in monocytes. THP-1 monocytes, however, contain a
unique defect in the production of PAI-2 in that the PAI-2 transcript is tr
uncated and the expressed protein inactive (1). Here we describe the basis
of this mutation in THP-1 cells. Southern blot analysis of THP-1-derived ge
nomic DNA indicated that there were no obvious deletions in the structure o
f the PAI-2 gene. However, assessment of the THP-1-derived PAI-2 transcript
by RT-PCR indicated that only exons seven and eight of the normal PAI-2 mR
NA could be detected. Cloning of the 5' region of the PAI-2 mRNA by 5-'RACE
indicated that the PAI-2 cDNA derived from THP-1 cells is approximately 13
29 bp long and contains 180 bp of sequence derived from intron 5, followed
by sequences corresponding ro exons seven and eight of the-normal PAI-2 mRN
A. The presence of the intron five fragment in endogenous THP-1 derived PAI
-2 mRNA was confirmed by Northern blotting. The absence of any wild-type PA
I-2 mRNA in these cells suggests that one copy of the PAI-2 allele has been
deleted. The remaining allele producing the truncated mRNA appears to have
undergone a translocation event and contains a mutation that has disrupted
the splicing of the PAI-2 primary transcript.